Oncolytics Biotech Inc. (TSX:ONC)
Canada · Delayed Price · Currency is CAD 1.420
+0.030 (2.16%)
Inactive · Last trade price on Aug 22, 2025
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-1.09M CAD
Market Cap
142.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Oncolytics Biotech News
- 20 hours ago - Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer - GlobeNewsWire
- 7 days ago - Oncolytics Reports Progress In REO 033 Trial, Plans FDA Meeting Ahead; Shares Jump - Nasdaq
- 7 days ago - Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - GlobeNewsWire
- 4 weeks ago - Oncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044 - Nasdaq
- 4 weeks ago - Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - GlobeNewsWire
- 6 weeks ago - Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - GlobeNewsWire
- 7 weeks ago - Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors - GlobeNewsWire